Subsequently, an Italian group 31b studying a similarly sized population, showed a highly significant difference in favor of co-amoxyclav (Augmentin) compared with placebo in patients with standardized disease severity.
1
—
—
Subsequently, an Italian group 31b studying a similarly sized population, showed a highly significant difference in favor of co-amoxyclav (Augmentin) compared with placebo in patients with standardized disease severity.